HC Wainwright Has Optimistic Outlook of MLYS Q3 Earnings

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) – Equities researchers at HC Wainwright increased their Q3 2026 EPS estimates for Mineralys Therapeutics in a research report issued to clients and investors on Thursday, August 13th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings per share of ($0.54) for the quarter, up from their prior estimate of ($0.56). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Mineralys Therapeutics’ current full-year earnings is ($4.45) per share. HC Wainwright also issued estimates for Mineralys Therapeutics’ Q4 2026 earnings at ($0.58) EPS, FY2026 earnings at ($4.40) EPS, FY2027 earnings at ($2.12) EPS, FY2028 earnings at ($0.96) EPS, FY2029 earnings at $1.12 EPS and FY2030 earnings at $4.13 EPS.

Several other research analysts have also recently weighed in on MLYS. Wall Street Zen cut shares of Mineralys Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Jefferies Financial Group reissued a “hold” rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Friday, July 17th. Finally, Zacks Research lowered Mineralys Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Thursday, August 13th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Mineralys Therapeutics presently has an average rating of “Hold” and an average target price of $49.33.

Mineralys Therapeutics Stock Up 4.2%

Shares of NASDAQ:MLYS opened at $26.34 on Monday. The firm has a fifty day moving average price of $26.82 and a two-hundred day moving average price of $27.23. The company has a debt-to-equity ratio of 0.18, a current ratio of 34.46 and a quick ratio of 34.46. Mineralys Therapeutics has a one year low of $14.53 and a one year high of $47.65. The company has a market cap of $2.33 billion, a price-to-earnings ratio of -6.21 and a beta of 0.68.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its earnings results on Wednesday, August 12th. The company reported ($2.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($2.30).

Insider Activity at Mineralys Therapeutics

In other Mineralys Therapeutics news, CEO Jon Congleton sold 75,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $26.14, for a total value of $1,960,500.00. Following the completion of the transaction, the chief executive officer owned 614,321 shares of the company’s stock, valued at $16,058,350.94. The trade was a 10.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Eric Warren sold 104,124 shares of the stock in a transaction on Friday, June 26th. The stock was sold at an average price of $25.90, for a total transaction of $2,696,811.60. Following the completion of the transaction, the insider directly owned 38,400 shares in the company, valued at $994,560. The trade was a 73.06% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 224,333 shares of company stock worth $5,806,213 in the last 90 days. 18.94% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in MLYS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Mineralys Therapeutics by 4.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,085 shares of the company’s stock worth $271,000 after acquiring an additional 702 shares in the last quarter. Navalign LLC bought a new stake in shares of Mineralys Therapeutics in the 4th quarter worth approximately $33,000. Velan Capital Investment Management LP boosted its stake in shares of Mineralys Therapeutics by 0.6% in the 3rd quarter. Velan Capital Investment Management LP now owns 175,600 shares of the company’s stock valued at $6,659,000 after purchasing an additional 1,000 shares in the last quarter. Royal Bank of Canada boosted its stake in shares of Mineralys Therapeutics by 262.3% in the 4th quarter. Royal Bank of Canada now owns 1,529 shares of the company’s stock valued at $56,000 after purchasing an additional 1,107 shares in the last quarter. Finally, KBC Group NV bought a new position in shares of Mineralys Therapeutics during the 1st quarter valued at $33,000. Institutional investors own 84.46% of the company’s stock.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.